U.S. Onychomycosis Market Size & Outlook, 2023-2030
U.S. onychomycosis market, 2018-2030 (US$M)
Related Markets
U.S. onychomycosis market highlights
- The U.S. onychomycosis market generated a revenue of USD 1,288.3 million in 2023 and is expected to reach USD 1,704.7 million by 2030.
- The U.S. market is expected to grow at a CAGR of 4.1% from 2024 to 2030.
- In terms of segment, topical was the largest revenue generating treatment in 2023.
- Topical is the most lucrative treatment segment registering the fastest growth during the forecast period.
Onychomycosis market data book summary
| Market revenue in 2023 | USD 1,288.3 million |
| Market revenue in 2030 | USD 1,704.7 million |
| Growth rate | 4.1% (CAGR from 2023 to 2030) |
| Largest segment | Topical |
| Fastest growing segment | Topical |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oral, Topical |
| Key market players worldwide | GSK PLC, Abbott Laboratories, Pfizer Inc, Bausch Health Companies Inc, Bayer AG, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, Merck & Co Inc, Novartis AG ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, U.S. accounted for 36.6% of the global onychomycosis market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. onychomycosis market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 210.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Onychomycosis Market Scope
Onychomycosis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. onychomycosis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to onychomycosis market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 57.65% in 2023. Horizon Databook has segmented the U.S. onychomycosis market based on oral, topical covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. onychomycosis market is driven by various factors, including rising awareness about onychomycosis treatment options and the presence of a large number of market players.
Moreover, these players are adopting various strategies, such as product launches and approvals, to expand their market share. For instance, in July 2021, Lupin introduced a Tavaborole Topical Solution in the U.S. for onychomycosis.
In addition, major key players are operating in the market in North America. Some of the key players operating in the U.S. are Merck & Co., Inc., Pfizer, Inc., Abbott, and Bausch Health Companies, Inc.
Reasons to subscribe to U.S. onychomycosis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. onychomycosis market databook
-
Our clientele includes a mix of onychomycosis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. onychomycosis market , including forecasts for subscribers. This country databook contains high-level insights into U.S. onychomycosis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. onychomycosis market size, by treatment, 2018-2030 (US$M)
U.S. Onychomycosis Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
